Alnylam Pharmaceuticals, Inc. (United States) has no DMF, CEP or site registration linked in our records. 3 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Alnylam Pharmaceuticals, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/alnylam-pharmaceuticals-inc

Overview

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development of RNAi therapeutics. The company focuses on genetic-driven and rare diseases with a comprehensive pipeline leveraging their RNA interference platform.

Therapeutic areas

Genetic DiseasesCardiometabolic DiseasesRare Diseases

FDA compliance signals

3 FDA enforcement records linked to this company.

  • 4832025-02-25

    Component written specification

  • 4832025-02-25

    Record maintenance 1 year (except exempt OTC)

  • 4832025-02-25

    Quality control unit review of records

For suppliers

Is this Alnylam Pharmaceuticals, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.